Prevalence of Drug Interaction in Severely Obese Individuals and Associated Factors: Baseline Results from a Clinical Trial

Modesto, Ana Carolina Figueiredo; Silveira, Érika Aparecida; Rodrigues, Ana Paula Santos; Lima, Dione Marçal; Provin, Mércia Pandolfo; Amaral, Rita Goreti

doi:10.3390/scipharm88040048

Cited by 2 publications

(1 citation statement)

References 45 publications

(62 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Consequently the prevalence of DDI in the current study is very low (1.0%) compared to studies of DDIs for people with diabetes conducted in India, Pakistan, Finland, France and Brazil which reported 39%-62%. 59-63 In line with the findings in this study, only 1.7% of the interactions were reported to be severe in a study conducted in Brazil. 64 Similarly, no severe interactions was reported in a study conducted in India that reported only moderate DDIs.…”

Section: Discussionsupporting

confidence: 86%

Assessment of Potentially Inappropriate Prescribing for People With Type 2 Diabetes Mellitus Using IMPACT2DM, a New Explicit Tool

Ayalew

Dieberg

Quirk

et al. 2022

Journal of Pharmacy Practice

View full text Add to dashboard Cite

Background People with type 2 diabetes mellitus (T2DM) are at greater risk of potentially inappropriate prescribing (PIP) due to multiple comorbidities and polypharmacy. IMPACT2DM (Inappropriate Medication Prescribing Assessment Criteria for Type 2 Diabetes Mellitus) is a tool designed to identify PIP for adults with T2DM. Objectives To assess PIP for adults with T2DM in Ethiopia using the IMPACT2DM and to test the face validity and clinical validity of the tool. Methods A cross-sectional study was undertaken using data extracted retrospectively from the medical records of adults being managed for T2DM at Debretabore Hospital. PIP was assessed using IMPACT2DM. Some items/item components of IMPACT2DM were modified to increase the tool’s applicability for the outpatient setting, to clarify content or to use the terms most common in this particular setting. Multivariant logistic regression analyses were conducted to identify factors associated with PIP. Results More than 90% of medical records had at least 1 PIP. Prescribing omission (80.9%) was the most commonly identified type of PIP. Adults with prescribing omissions are more likely to be ≥40 years old or to be prescribed with <5 medications. Adults with dosing problems were more likely ≥50 years old, or have had a fasting blood sugar (FBS) level out of the target range (80-130 mg/dL). Conclusions IMPACT2DM is a clinically valid PIP identification tool for application in an Ethiopian outpatient setting. Health professionals should be alert to check for potential prescribing omissions for adults ≥40 years old and dosing problems for adults with an FBS level out of the target range or >50 years.

show abstract

Section: Discussionsupporting

confidence: 86%

Assessment of Potentially Inappropriate Prescribing for People With Type 2 Diabetes Mellitus Using IMPACT2DM, a New Explicit Tool

Ayalew

Dieberg

Quirk

et al. 2022

Journal of Pharmacy Practice

View full text Add to dashboard Cite

show abstract

Obesity-related drug transporter expression alterations in human liver and kidneys

Kosicka-Noworzyń,

Romaniuk-Drapała,

Sheng

et al. 2024

Pharmacol. Rep

View full text Add to dashboard Cite

Background Pathophysiological changes associated with obesity might impact various drug pharmacokinetics (PK) parameters. The liver and kidneys are the primary organs involved in drug clearance, and the function of hepatic and renal transporters is critical to efficient drug elimination (or reabsorption). Considering the impact of an increased BMI on the drug’s PK is crucial in directing dosing decisions. Given the critical role of transporters in drug biodisposition, this study investigated how overweight and obesity affect the gene expression of renal and hepatic drug transporters. Methods Human liver and kidney samples were collected post-mortem from 32 to 28 individuals, respectively, which were divided into the control group (lean subjects; 18.5 ≤ BMI < 25 kg/m2) and the study group (overweight/obese subjects; BMI ≥ 25 kg/m2). Real-time quantitative PCR was performed for the analysis of 84 drug transporters. Results Our results show significant changes in the expression of genes involved in human transporters, both renal and hepatic. In liver tissue, we found that ABCC4 was up-regulated in overweight/obese subjects. In kidney tissue, up-regulation was only observed for ABCC10, while the other differentially expressed genes were down-regulated: ABCA1, ABCC3, and SLC15A1. Conclusions The observed alterations may be reflected by the differences in drug PK between lean and obese populations. However, these findings need further evaluation through the proteomic and functional study of these transporters in this patient population.

show abstract

Prevalence of Drug Interaction in Severely Obese Individuals and Associated Factors: Baseline Results from a Clinical Trial

Cited by 2 publications

References 45 publications

Assessment of Potentially Inappropriate Prescribing for People With Type 2 Diabetes Mellitus Using IMPACT2DM, a New Explicit Tool

Assessment of Potentially Inappropriate Prescribing for People With Type 2 Diabetes Mellitus Using IMPACT2DM, a New Explicit Tool

Obesity-related drug transporter expression alterations in human liver and kidneys

Contact Info

Product

Resources

About